Research library

D

grade

Not reported in abstract.

summary

A

grade

Procizumab was well-tolerated in a small group of healthy males, with no serious adverse events reported and a terminal elimination half-life ranging from 24 to 53 hours depending on the dose.

Terminal elimination half-life of 24 h (3 mg/kg), 34 h (6 mg/kg), and 53 h (12 mg/kg).

summary

C

grade

Procizumab (PCZ) was well tolerated in animal models with no severe adverse effects noted, but further studies in humans are needed to confirm these findings.

150 mg/kg PCZ in mice, n=126; 350 mg/kg PCZ in monkeys, n=10.

summary

B

grade

The gradient boosting machine model achieved an AUC of 0.890 for predicting in-hospital mortality in SA-AKI patients on CRRT, but its clinical utility may be limited by the study's retrospective design.

AUC of 0.890 in training cohort, n=1217.

summary

D

grade

Bremelanotide showed lower degradation under acidic conditions and significant susceptibility to oxidative conditions, with eight degradation products identified.

Coefficient of determination (r²) of 0.9993 over the concentration range of 25-150 µg mL-1.

summary

C

grade

The study suggests that adding extracyclic arginine residues to melanocortin peptides may improve their ability to reduce food intake in mice, but the clinical implications for humans are not established.

Not reported in abstract.

summary

D

grade

Women with hypoactive sexual desire disorder reported engaging in 'mercy sex' about 2.5 times per month, which may affect the outcomes of clinical trials for HSDD treatments.

Women engaged in 'mercy sex' approximately 2.5 times/month.

summary

D

grade

This review highlights the need for standardized methodologies in clinical trials for HSDD to improve the quality of evidence and facilitate better clinical interpretation.

Not reported in abstract.

summary

C

grade

Bremelanotide did not enhance sexual reward or affect melanocortin receptor expression in female Syrian hamsters, suggesting limited understanding of its neurobiological action.

Not reported in abstract.

summary

D

grade

This review highlights the progress and gaps in pharmacological treatments for HSDD, emphasizing the need for standardized trial methodologies and comprehensive reporting.

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

C

grade

Bremelanotide and other FDA-approved drugs may have potential as inhibitors of SARS-CoV-2 proteins, but experimental validation is necessary before considering clinical application.

summary

D

grade

Melanocortin receptors are linked to several inflammatory diseases, and genetic variations may influence these associations, but specific evidence and clinical significance are not detailed in this review.

summary

D

grade

The review discusses the need for effective management of vasomotor symptoms and libido in breast cancer patients, emphasizing the potential role of novel agents like bremelanotide, but lacks specific data to support their use.

summary